Relationship between P-glycoprotein and second-generation antipsychotics.
about
Pharmacogenetics and outcome with antipsychotic drugsPlasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophreniaClinically significant psychotropic drug-drug interactions in the primary care setting.Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.Psychotropic drug-drug interactions involving P-glycoprotein.Pharmacogenetics of olanzapine metabolism.Clinically significant drug interactions with atypical antipsychotics.Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.Pharmacogenetics of second-generation antipsychotics.Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.ABC transporters at the blood-brain barrier.Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians.Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia.Effects of green tea extracts on the pharmacokinetics of quetiapine in rats.ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting.The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects.Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis.Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report
P2860
Q26852807-713D9C50-29FE-4CBF-B134-C28B833DEA27Q34418688-41CC4ABD-E34C-434F-947F-F51EAC3B9530Q34655540-C520E7D8-4BE3-40A4-BC9A-8A78055C986EQ35104220-D91A7922-0B1F-4C61-B759-6894A520365EQ35996706-EE456034-2A47-44DB-938A-F2976CE3F6F0Q37344782-1C6DD117-D6A7-4C86-9FCB-3FA03E91629CQ37709400-6EF4C46C-315F-4BE9-A2F9-79E7CB065A31Q38047816-06625A1C-3F20-4815-B388-94E3AD161941Q38127716-45523D48-E75F-4A4A-8AB7-D22AEE8228B2Q38156416-181AB0F0-7329-43FA-A706-17334BD1D772Q38185057-86FF557E-FDE2-4C91-A904-DCE593355C6BQ38217628-6C977549-D10E-45F5-912D-FD154E9CE160Q38734067-87637D70-5777-463F-89F9-DD5F0A040BFBQ38783122-C0BF0249-ED56-4DD7-A13E-4D3E0D1AAAAEQ39117848-DAC5033C-C51B-4E7D-BBD7-DABAEC0E3AE6Q39145955-B6624676-685B-4199-B87E-6594FFC64B46Q40571585-35E65F37-9158-4E2B-8023-2B64A301F7A9Q41887815-9D1EFC11-430C-4728-9829-A47259C72783Q48102778-FFF3EEB8-7004-41AC-90F3-6A506DAD2CB1Q48273932-38D18CF2-1E94-4788-AC4D-F6219D82754DQ51015027-A5895F05-C42C-4500-AC46-25CE629E2A85Q55308829-55E51726-B2F0-428F-AE22-D848C2FD87EBQ58781437-3E2096F6-DEB6-49CF-BF82-A0DD4B3451DB
P2860
Relationship between P-glycoprotein and second-generation antipsychotics.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Relationship between P-glycoprotein and second-generation antipsychotics.
@ast
Relationship between P-glycoprotein and second-generation antipsychotics.
@en
Relationship between P-glycoprotein and second-generation antipsychotics.
@nl
type
label
Relationship between P-glycoprotein and second-generation antipsychotics.
@ast
Relationship between P-glycoprotein and second-generation antipsychotics.
@en
Relationship between P-glycoprotein and second-generation antipsychotics.
@nl
prefLabel
Relationship between P-glycoprotein and second-generation antipsychotics.
@ast
Relationship between P-glycoprotein and second-generation antipsychotics.
@en
Relationship between P-glycoprotein and second-generation antipsychotics.
@nl
P2860
P50
P356
P1433
P1476
Relationship between P-glycoprotein and second-generation antipsychotics
@en
P2093
Mariska de Roo
P2860
P304
P356
10.2217/PGS.11.55
P577
2011-08-01T00:00:00Z